NEW YORK, NY / ACCESSWIRE / January 6, 2017 / The Dow Jones Industrial Average pulled back Thursday as investors sold off financial equities, which had been amongst the best performers since the Presidential Election, in favor of gold and government bonds. The Dow fell by as much as 131 points before settling to close at 19,899.29, a decline of 0.21 percent and the S&P 500 Index fell 0.08 percent to close at 2,269.00. The S&P 500 financials sector dropped 1.02 percent, while Dow components American Express, Goldman Sachs Group, J.P. Morgan Chase and Travelers all posted declines.

Register with us now for your free membership and gain access to our latest research reports at: RDInvesting.com

"Most people are trying to extend this positive sentiment from last year, but we do have some caution in the coming months something could turn," said Jeroen Blokland, a senior portfolio manager at Robeco, who currently has a "neutral" view on equities.

Apple Inc. (NASDAQ: AAPL)

Get Your Up-To-Date Apple Research Report Click Here

Apple's shares gained 0.51 percent to close at $116.61 a share Thursday. The stock traded between $115.81 and $116.86 on volume of 22.19 million shares traded. The company reported that Apple's App Store experienced its busiest single day ever on New Year's Day with $240 million in purchases. Purchases from the app store broke all-time holiday records in December with sales topping $3 billion.

"2016 was a record-shattering year for the App Store, generating $20 billion for developers, and 2017 is off to a great start with Jan. 1 as the single biggest day ever on the App Store," said Philip Schiller, Apple's senior vice president of Worldwide Marketing. "We want to thank our entire developer community for the many innovative apps they have created ? which together with our products ? help to truly enrich people's lives."

Mylan NV (NASDAQ: MYL)

Get Your Up-To-Date Mylan NV Research Report Click Here

Mylan's shares declined 1.19 percent to close at $39.16 a share Thursday. The stock traded between $38.77 and $39.47 on volume of 5.80 million shares traded. Analysts at Citi downgraded the EpiPen maker's rating to "neutral" from "buy", citing potentially weaker financial results due to drug pricing difficulties.

"We anticipate ongoing net pricing pressure on EpiPen as public and political scrutiny on the franchise continues," analyst Liav Abraham wrote in a note to clients Wednesday. "With valuation currently roughly in line with the peer group average, we see limited potential for meaningful multiple expansion."

Mylan CEO Heather Bresch testified before Congress in September to defend the company's more than 500 percent price hike of its anti-allergy EpiPen product in the previous years. Consensus of analyst are of view that the company will outperform the market.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com